We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals

245 hedge funds and large institutions have $730M invested in Aurinia Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 64 increasing their positions, 90 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 20

120% more capital inflows, than outflows

Capital inflows: $160M | Capital outflows: $72.6M

82% more call options, than puts

Call options by funds: $16.1M | Put options by funds: $8.82M

11% more funds holding

Funds holding: 220 → 245 (+25)

6.75% more ownership

Funds ownership: 43.43% → 50.18% (+6.8%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

29% less repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 90

Holders
245
Holders Change
+25
Holders Change %
+11.36%
% of All Funds
3.2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
49
Increased
64
Reduced
90
Closed
20
Calls
$16.1​M
Puts
$8.82​M
Net Calls
+$7.23​M
Net Calls Change
+$1.76​M

AUPH Hedge Fund Activity: Q3 2025 in Review

245 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2025, worth a combined $730M — up 47% from $497M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new AUPH positions and 20 closed out — a net gain of 29 holders — while 64 added to existing stakes and 90 trimmed.

The largest buyer was Arrowstreet Capital, adding an estimated $25.1M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.8M sold.

  • 245 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2025, up from 220 in Q2 2025.
  • Funds reported $730M of Aurinia Pharmaceuticals stock for Q3 2025, up 47% quarter-over-quarter.
  • 49 funds opened new Aurinia Pharmaceuticals positions in Q3 2025 and 20 closed out, a net change of +29 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q3 2025 was Arrowstreet Capital, an estimated $25.1M added.
  • The largest Aurinia Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $13.8M sold.

Based on aggregated 13F filings for Q3 2025.